Open Menu

Scrambler Therapy® device (international patent)

The Scrambler Therapy® device is a U.S. FDA 510(k)-cleared (# K142666 for Delta International Services & Logistics) and European CE mark-certified pain therapy medical device for the non-invasive treatment of chronic neuropathic and oncologic pain. Treatment using the Scrambler Therapy® device avoids the harmful, potentially fatal, adverse side effects.

The Scrambler Therapy® device has been used to successfully treat thousands patients worldwide, where it has been shown to be effective in treating neuropathic and oncologic pain. Scrambler Therapy is a stand-alone medical electroanalgesia device, and does not require combinations with other analgesic therapies.

This medical device (international patent) has been developed in Italy by Prof. Giuseppe Marineo .

Scrambler Therapy scientific and clinical research (International Patent) is currently available in just one medical device labeled Scrambler Therapy® Technology MC-5A. On May 22, 2015 the FDA authorized the marketing of the Scrambler Therapy® Technology device (Clearance: # K142666 for Delta International Services & Logistics).

This medical device replacing the previous old version, known in the US as the Calmare® device.

Clinical efficacy

Scrambler Therapy® if correctly used is a control tool for severe chronic neuropathic and cancer pain. Scrambler Therapy® is very effective, non-invasive and mainly to be used in ambulatory care and hospital facilities. If carried out correctly the analgesic effect during the treatment is very rapid. In just a couple of seconds the pain perception completely disappears. This is true even in cases where pain is of high intensity and non responsive or poorly responsive to opioids or other electro-analgesia devices such as TENS or implanted devices.

Short and long term effects of a single treatment cycle depend on the type of pathology and other variables. In most cases of benign pain one treatment cycle is enough to produce pain relief for at least two months, but can even exceed 12 months if neuropathic damage is limited (mono-radicular) or the pathology has no evolution feature. Other variables that influence the treatment outcome are pharmaceutical interactions. Immediate analgesic efficacy during the treatment is a constant factor regardless of pathology and pain intensity.

For more information visit the Official Scrambler Therapy® scientific and clinical information website .

International distribution

DIS&L through its law firm is the only company authorized to sign international exclusive agreements in all international area , provide maintenance and distributor support for method usage training and other logistics needs. To request a national exclusive agreement the candidate distributor must have minimum requirements listed on the “ Distributor Requirement ” page. Indications.

Copyright © DIS&L. All rights reserved